Autopsy report · NCT03353220

Predictors of Lorcaserin-Induced Weight Loss

“The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 1 month before it stopped.
• 32 participants enrolled.
• Results were posted on the registry 1 year 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Columbia University

Sponsor type

University, hospital or other

Conditions

Overweight and Obesity

Interventions

Belviq; Placebo

Participants

32

Sites

1

Countries

United States

Trials that died the same way

• Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab
  “drug withdrawn from market” (60% match in meaning)
• Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
  “Lack of efficacy of the drug; no safety concern” (57% match in meaning)
• Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis
  “The IND has been withdrawn from FDA” (57% match in meaning)
• Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer
  “Withdrawn due to toxicity” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.